Abstract:
The present invention provides a process for purifying natural gas, comprising removing mercaptans from a natural gas stream by a combination of an amine-based separation unit and a selective oxidation unit to obtain a purified natural gas stream, wherein at least part of the mercaptans are converted into at least elemental sulphur in the selective oxidation unit by selective catalytic oxidation.
Abstract:
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
Abstract:
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Abstract:
The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
Abstract:
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Abstract:
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Abstract:
The present invention provides a process for the selective oxidation of hydrogen sulphide contained in a hydrogen sulphide-containing hydrocarbon feed gas to elemental sulphur. The hydrogen sulphide-containing hydrocarbon feed gas and a sulphur dioxide-containing gas are supplied to a reaction zone containing a TiO2-comprising catalyst, wherein elemental sulphur and a gaseous stream depleted in hydrogen sulphide are formed. The gas feeds are contacted with the TiO2 containing catalyst at elevated pressure and at a temperature in the range of from 120 and below 160° C., under such conditions that the elemental sulphur formed is essentially in liquid form. At least part of the sulphur dioxide-containing gas is obtained by combusting elemental sulphur to obtain a gaseous mixture of sulphur dioxide and nitrogen and then concentrating the gaseous mixture to provide the sulphur dioxide-containing gas.
Abstract:
The present invention provides a process for purifying natural gas, comprising removing mercaptans from a natural gas stream by a combination of an amine-based separation unit and a selective oxidation unit to obtain a purified natural gas stream, wherein at least part of the mercaptans are converted into at least elemental sulphur in the selective oxidation unit by selective catalytic oxidation.
Abstract:
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.
Abstract:
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula 1: wherein Q is an optionally substituted azetidinyl, pyrrolidinyl, piperidyl, and indolinyl; or Q is NR25R26; and A, R5, R6, R7, R8, R9, R25, R26 and Ar are substituents.